Optimising the management of pulmonary arterial hypertension patients: Emergency treatments

European Respiratory Review

Volumn 19, Issue 117, 2010, Pages 204-211

  Delcroix, M ^a   Naeije, R ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Emergencies; Organisation of care; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMIODARONE; BOSENTAN; CATECHOLAMINE; DIGOXIN; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; LEVOSIMENDAN; MILRINONE; NITRIC OXIDE; NORADRENALIN; PROPYLTHIOURACIL; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTAMINE; SILDENAFIL; SITAXSENTAN; STEROID; UNIPROST; VASOPRESSIN; VITAMIN K GROUP;

ANEMIA; ANESTHESIA INDUCTION; ARTIFICIAL VENTILATION; BELGIUM; BLOODSTREAM INFECTION; CARDIOVERSION; CATHETER INFECTION; CATHETER OCCLUSION; CAUSE OF DEATH; CLINICAL PROTOCOL; DISEASE COURSE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EMERGENCY TREATMENT; HEALTH CARE DELIVERY; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPERTHYROIDISM; HYPOTENSION; INTENSIVE CARE UNIT; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PATIENT CARE; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PORTOPULMONARY HYPERTENSION; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; PULMONARY HYPERTENSION; RADIOFREQUENCY ABLATION; RESPIRATORY FAILURE; RESUSCITATION; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; THROMBOCYTOPENIA;

CRITICAL PATHWAYS; EMERGENCY MEDICAL SERVICES; HUMANS; HYPERTENSION, PULMONARY; RESPIRATORY INSUFFICIENCY; RESUSCITATION;

EID: 78449271973     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00004910     Document Type: Review

References (37)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a National Registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
3. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
4. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
5. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
6. Hoeper MM, Galie N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 341-344.
7. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35: 1286-1293.
8. Kurzyna M, Zylkowska J, Fijalkowska A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol Pol 2008; 66: 1033-1039.
9. Zamanian RT, Haddad F, Doyle RL, et al. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007; 35: 2037-2050.
10. Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 2001; 22: 517-527.
11. Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36: S75-S88.
12. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-596.
13. Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004; 32: 1035-1040.
14. Deb B, Bradford K, Pearl RG. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28: 795-799.
15. Lobato EB, Beaver T, Muehlschlegel J, et al. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth 2006; 96: 317-322.
16. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.
17. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34: 2814-2819.
18. Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 2009; 49: 109-115.
19. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30: 2548-2552.
20. Bhorade S, Christenson J, O'Connor M, et al. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999; 159: 571-579.
21. Christenson J, Lavoie A, O'Connor M, et al. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt with-drawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000; 161: 1443-1449.
22. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
23. Dantzker DR, D'Alonzo GE, Bower JS, et al. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. Am Rev Respir Dis 1984; 130: 412-416.
24. Achouh L, Montani D, Garcia G, et al. Pulmonary arterial hypertension masquerading as severe refractory asthma. Eur Respir J 2008; 32: 513-516.
25. Mekontso DA, Charron C, Devaquet J, et al. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med 2009; 35: 1850-1858.
26. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153: 127-132.
27. Goldstein JA, Harada A, Yagi Y, et al. Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 1990; 16: 181-189.
28. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
29. Hemnes AR, Gaine SP, Wiener CM. Poor outcomes associated with drainage of pericardial effusions in patients with pulmonary arterial hypertension. South Med J 2008; 101: 490-494.
30. Jais X. Hemoptysis in pulmonary arterial hypertension (PAH): a life-threatening complication. Am J Respir Crit Care Med 2009; 179: A2667.
31. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45: 1691-1699.
32. Price LC, Montani D, Jais X, et al. Noncardiothoracic nonobstetric surgery in mild-moderate pulmonary hypertension. Eur Respir J 2010; 35: 1294-1302.
33. Lebourveau P, Williamson TL, Bartolome SD. Peri-operative management of pulmonary hypertension patients. Am J Respir Crit Care Med 2009; 179: A3344.
34. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.
35. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56: 170-172.
36. O'Callaghan DS, Moutet A, Jais X, et al. Catheter related-infections in pulmonary hypertension patients treated by continuous intravenous epoprostenol: experience of the French referral centre. Am J Respir Crit Care Med 2010; 181: A3337.
37. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008; 5-9